Abstracts Archive - Page 2278 of 2607 - ACR Meeting Abstracts

Abstract Number: 2349 • 2013 ACR/ARHP Annual Meeting
Abatacept and Anti-Tumor Necrosis Factor Monoclonal Antibodies: Efficacy and Safety Comparisons
M Schiff¹, Maxime Dougados², Roy Fleischmann³, J Fay⁴ and M Maldonado⁴, ¹University of Colorado, Denver, CO, ²Rheumatology, Hopital Cochin, Descartes University, Paris, France, ³University of Texas Southwestern Medical Center, Dallas, TX, ⁴Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: A paucity of clinical trial data exists comparing the efficacy and safety of biologic therapies for RA. This study evaluated remission rates and safety…
Abstract Number: 2350 • 2013 ACR/ARHP Annual Meeting
Effects Of VX-509, An Investigational Oral Selective Janus Kinase 3 (JAK3) Inhibitor, On Patient-Reported Outcomes In a Phase 2A Study Of Patients With Active Rheumatoid Arthritis
Vibeke Strand¹, Ellison Suthoff², Roy Fleischmann³, Montserrat Vera-Llonch⁴, John Jiang², Yanqiong Zhang² and Nils Kinnman⁵, ¹Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, ²Vertex Pharmaceuticals Incorporated, Cambridge, MA, ³Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, TX, ⁴Vertex Pharamceuticals Incorporated, Cambridge, MA, ⁵Vertex Pharmaceuticals Incorporated, Eysins, Switzerland
Background/Purpose: VX-509 is an oral JAK3 inhibitor being evaluated as a treatment for RA. Safety and efficacy results from a phase 2a, 12-week, randomized…
Abstract Number: 2312 • 2013 ACR/ARHP Annual Meeting
Experiences Of Older People Living With Ankylosing Spondylitis
Jane Martindale, Elham Kashefi and Lynne Goodacre, Faculty of Health and Medicine, Lancaster University, Lancaster, United Kingdom
Background/Purpose: With an increasing demographic of ageing, more people may be living longer with a long-term health condition. There may be implications in terms of…
Abstract Number: 2310 • 2013 ACR/ARHP Annual Meeting
Nurse Training; Confidence and Competence For Educating Patients Commencing Methotrexate Therapy
Sandra M. Robinson¹, Andrew Hassell², Sarah Ryan³, Nicola Adams⁴, Peta S. Heslop¹ and David Walker⁵, ¹R&D, North Tyneside General Hospital, North Shields, United Kingdom, ²Rheumatology, School of Medicine (Keele Campus), Keele, United Kingdom, ³Keele University, Staffordshire, United Kingdom, ⁴Rehabilitation, Northumbria University, Newcastle Upon Tyne, United Kingdom, ⁵Dept of Rheumatology, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
Background/Purpose: The education of patients is a central part of the nursing role in the UK. Nowhere is it more important than in relation to…
Abstract Number: 2311 • 2013 ACR/ARHP Annual Meeting
Impact Of Healing Architecture In a Rheumatology Outpatient Clinic
Gunhild Bukh¹, Erik Kehn Jensen², Anne Marie Munk Tommerup³ and Ole Rintek Madsen⁴, ¹Dept. of Rheumatology, Copenhagen University Hospital Gentofte, Hellerup, Denmark, ²Kehn & Warnøe, Copenhagen, Denmark, ³Danish Architecture Centre, Copenhagen, Denmark, ⁴Copenhagen University Hospital Gentofte, Copenhagen, Denmark
Background/Purpose: Healing Architecture (HA) is a design concept primarily aimed at reducing factors of stress in the physical environment both for the patient and for…
Abstract Number: 2313 • 2013 ACR/ARHP Annual Meeting
Pain-Related Anxiety As a Barrier To Use Of Methotrexate In Rheumatoid Arthritis: Comparing Conventional Vial, Needles, and Syringe With An Investigational Auto-Injector In Healthy Volunteers
Victoria L. Ruffing¹ and Kaushik J. Dave², ¹Medicine JHAAC, Johns Hopkins University, Baltimore, MD, ²Product Development, Antares Pharma Inc, Ewing, NJ
Background/Purpose: Methotrexate (MTX) is the cornerstone of rheumatoid arthritis (RA) treatment. Limitations of systemic exposure of oral MTX can affect its efficacy. Subcutaneous (SC) MTX…
Abstract Number: 2315 • 2013 ACR/ARHP Annual Meeting
Reducing The Need For Total Knee Arthroplasty: The Experience Of a Multidisciplinary Osteoarthritis Clinic
Caroline Jones¹, Angelo Papachristos¹ and Laurence A. Rubin², ¹Physiotherapy, St Michael's Hospital, Toronto, ON, Canada, ²Rheumatology, St. Michael Hospital, Toronto, ON, Canada
Background/Purpose: St. Michael’s Hospital (SMH) is a tertiary care facility located in Toronto, serving a diverse social, economic and cultural urban population. In 2008, a…
Abstract Number: 2316 • 2013 ACR/ARHP Annual Meeting
Anti-Human TNF-Alpha Domain Antibody Construct, CEP-37247/Placulumab, Is As Efficacious As Other Leading TNF-Alpha-Blockade Therapies in a Humanized Mouse Model of Rheumatoid Arthritis
Matthew M. Seavey¹, Linglong Zou², Adam Clarke³, Anthony G. Doyle³, Roberta Weiss⁴, Aric Orbach⁵, Brad McIntyre⁶ and Merav Bassan⁷, ¹Nonclinical Development, Pharmacology, Teva Pharmaceuticals, Inc., West Chester, PA, ²GB&T, Teva Biopharmaceuticals, Rockville, MD, ³Discovery Biologics, Teva Pharmaceuticals, Inc., Sydney, Australia, ⁴Clinical Development, Teva Pharmaceuticals, Inc., Frazer, PA, ⁵Nonclinical Development, Pharmacology, Teva Pharmaceuticals, Inc., Netanya, Israel, ⁶Formulation, Teva Pharmaceuticals, Inc., West Cheater, PA, ⁷Teva R&D - Innovative Project Leadership, Teva Pharmaceuticals, Inc., Netanya, Israel
Background/Purpose: The cytokine tumor necrosis factor (TNF)alpha is a potent pro-inflammatory mediator involved in several autoimmune diseases including rheumatic arthritis and for over a decade…
Abstract Number: 2317 • 2013 ACR/ARHP Annual Meeting
Impact of PVA Coated Nanoparticles On Cellular Viability and Functionality of Immune Cells Obtained From Healthy Donors and Patients With Rheumatoid Arthritis Or Osteoarthritis
Cindy Strehl¹, Timo Gaber¹, Manuela Jakstadt¹, Martin Hahne¹, Saskia Schellmann¹, Barbara Szostak¹, Géraldine Coullerez², Heinrich Hofmann², Gerd Burmester³ and Frank Buttgereit⁴, ¹Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, ²Institute of Materials Powder Technology Laboratory, École polytechnique fédérale de Lausanne, Lausanne, Switzerland, ³Rheumatology and Clinical Immunology, Campus Mitte, Charite University Hospital, Berlin, Germany, ⁴Charité - Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Nanotechnology has developed into a key technology of the 21st century. Over the recent years, the number of nanotechnical products has received an enormous…
Abstract Number: 2318 • 2013 ACR/ARHP Annual Meeting
Disease Activity in Moderate and Severe Rheumatoid Arthritis At Discontinuation in 10-Year Open-Label Extension Studies With Etanercept
Michael E. Weinblatt¹, Joan M. Bathon², Michele Hooper³, Bojena Bitman⁴, Yue Yang⁵, David H. Collier⁶, James Chung⁷ and Mark C. Genovese⁸, ¹Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Columbia University, New York, NY, ³Amgen Global Safety, Amgen Inc., Thousand Oaks, CA, ⁴Amgen, Inc., San Francisco, CA, ⁵Assent Consulting, South San Francisco, CA, ⁶Amgen Inc., Thousand Oaks, CA, ⁷Amgen, Thousand Oaks, CA, ⁸Division of Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose: Retention rates may be used as a surrogate of long-term effectiveness of drug therapy in open-label studies. Studies have reported that patients (pts)…
Abstract Number: 2319 • 2013 ACR/ARHP Annual Meeting
Comparative Safety Of Biological Agents Among Medicare Rheumatoid Arthritis Patients
Huifeng Yun¹, Fenglong Xie², Elizabeth S. Delzell¹, Lang Chen³, Emily Levitan¹, James Lewis⁴, Kenneth G. Saag⁵, Timothy Beukelman⁶, Kevin L. Winthrop⁷, John Baddley⁸, Paul M. Muntner¹ and Jeffrey R. Curtis³, ¹Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Medicine, University of Pennsylvania, Philadelphia, PA, ⁵Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ⁶Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁷Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, ⁸Medicine, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Several new biologic disease-modifying antirheumatic drugs (DMARDs) have been approved for treatment of rheumatoid arthritis (RA) in United States. However, their comparative risks of…
Abstract Number: 2320 • 2013 ACR/ARHP Annual Meeting
Ultrasonographic Monitoring Of Response To Infliximab In Patients With Rheumatoid Arthritis
Xiaomei Leng¹, Weiguo Xiao², Xiaochun Zhu³, Zhonghui Xu¹, Wei Yu¹, Jing Lu², Jiakai Wang², Xiaoru Xia³, Yongji Li³, Yi Liu⁴, Yi Zhao⁴, Honghao Tang⁵, Dongbao Zhao⁶, Yeqing Shi⁶, Huji Xu⁷, Jun Bao⁷, Lin Chen⁷, Ling Lin⁷, Ling Zhou⁷, Guoqiang Chen⁸, Weihong Zhang⁸ and Yan Zhao¹, ¹Peking Union Medical College Hospital, Beijing, China, ²The First Hospital of China Medical University, Shenyang, China, ³The First Hospital of Wenzhou Medical College, Wenzhou, China, ⁴Department of Rheumatology and Immunology, West China Hospital of Sichuan University, Chengdu, China, ⁵West China Hospital of Sichuan University, Chengdu, China, ⁶Changhai Hospital of Shanghai, Shanghai, China, ⁷Shanghai Changzheng Hospital, Shanghai, China, ⁸The First People’s Hospital of Foshan, Foshan, China
Background/Purpose: To evaluate the efficacy of treatment with infliximab on joint inflammation and bone erosion in rheumatoid arthritis (RA) patients using ultrasonography. Methods: 80 eligible…
Abstract Number: 2321 • 2013 ACR/ARHP Annual Meeting
Long-Term Safety and Efficacy Of Certolizumab Pegol In Combination With Methotrexate In The Treatment Of Rheumatoid Arthritis: 5-Year Results From a 24-Week Randomized Controlled Trial and Open-Label Extension Study
Josef S. Smolen¹, Ronald van Vollenhoven², Arthur Kavanaugh³, Vibeke Strand⁴, Jiri Vencovsky⁵, Michael H. Schiff⁶, Robert Landewé⁷, Boulos Haraoui⁸, Susan Walker⁹ and Désirée van der Heijde¹⁰, ¹Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ²Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ³Division of Rheumatology Allergy and Immunology, University of California San Diego, San Diego, CA, ⁴Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, ⁵Institute of Rheumatology, Department of Clinical and Experimental Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁶Rheumatology Division, University of Colorado, Denver, CO, ⁷Academic Medical Center Amsterdam & Atrium Medical Center, Heerlen, Netherlands, ⁸Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada, ⁹UCB Pharma, Raleigh, NC, ¹⁰Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: In the RAPID2 randomized controlled trial (RCT; NCT00160602), certolizumab pegol (CZP) +MTX every 2 weeks (Q2W) improved signs and symptoms of rheumatoid arthritis (RA)…
Abstract Number: 2322 • 2013 ACR/ARHP Annual Meeting
Post–Hoc Analysis Showing Better Clinical Response With The Loading Dose Of Certolizumab Pegol In Japanese Patients With Active Rheumatoid Arthritis
Tsutomu Takeuchi¹, Kazuhiko Yamamoto^2,3, Hisashi Yamanaka⁴, Naoki Ishiguro⁵, Yoshiya Tanaka⁶, Katsumi Eguchi⁷, Akira Watanabe⁸, Hideki Origasa⁹, Mariko Kobayashi¹⁰, Toshiharu Shoji¹⁰, Nobuyuki Miyasaka¹¹ and Takao Koike¹², ¹Department of Rheumatology, Keio University, Tokyo, Japan, ²Department of Allergy and Rhaumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ³University of Tokyo, Tokyo, Japan, ⁴Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁵Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁶The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁷Sasebo City General Hospital, Sasebo, Nagasaki, Japan, ⁸Tohoku University, Sendai, Japan, ⁹Division of Biostatistics and Clinical Epidemiology, University of Toyama School of Medicine, Toyama, Toyama, Japan, ¹⁰UCB Pharma, Tokyo, Japan, ¹¹Tokyo Medical and Dental University, Tokyo, Japan, ¹²Rheumatology, NTT Sapporo Medical Center, Sapporo, Japan
Background/Purpose: Certolizumab pegol (CZP) with MTX (J-RAPID; NCT00791999) and without MTX (HIKARI; NCT00791921) has demonstrated rapid and sustained improvements in disease activity in Japanese patients…
Abstract Number: 2323 • 2013 ACR/ARHP Annual Meeting
Comprehensive Disease Remission Achieved By Certolizumab Pegol Treatment, and Factors Associated With Certolizumab Pegol Comprehensive Disease Remission, In Rheumatoid Arthritis Patients With Predominantly High Disease Activity
Yoshiya Tanaka¹, Kazuhiko Yamamoto², Tsutomu Takeuchi³, Hisashi Yamanaka⁴, Naoki Ishiguro⁵, Katsumi Eguchi⁶, Akira Watanabe⁷, Hideki Origasa⁸, Tadao Okamoto⁹, Yumiko Wada⁹, Toshiharu Shoji⁹, Nobuyuki Miyasaka¹⁰ and Takao Koike¹¹, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Department of Allergy and Rheumatology, The University of Tokyo, Tokyo, Japan, ³Keio University, Tokyo, Japan, ⁴Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁵Department of Orthopedic Surgery, Nagoya University, Nagoya, Japan, ⁶Sasebo City General Hospital, Sasebo, Japan, ⁷Tohoku University, Sendai, Japan, ⁸Division of Biostatistics and Clinical Epidemiology, University of Toyama School of Medicine, Toyama, Toyama, Japan, ⁹UCB Pharma, Tokyo, Japan, ¹⁰Department of Medicine and Rheumatology, Graduate School of Medicine and Dentistry, Tokyo Medical and Dental University, Tokyo, Japan, ¹¹NTT Sapporo Medical Center, Sapporo, Japan
Background/Purpose: The therapeutic goals of treating rheumatoid arthritis (RA) are clinical, structural and functional remissions.1,2 Simultaneously achieving all three has been referred to as comprehensive…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].